EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to

Fredrick Katongole, Tiyara Arumugam, Angus Jennings, Constantine Mutata, Patrick Ssebunya, Charity Wamboi, Alexandra Green, Mutsa Bwakura-Dangarembizi, Cissy Kityo, Abraham Siika, Moherndran Archary, Lungile Jafta und 10 weitere

Contemporary Clinical Trials · 2025

DOI: 10.1016/j.cct.2025.107963 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Contemporary Clinical Trials, 2025. Verfasst von Fredrick Katongole und 21 weiteren Autor:innen. Beteiligte Einrichtung: Baylor College of Medicine Children's Foundation, Kampala, Uganda. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, Piperazines, HIV Infections, Tenofovir. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, European & Developing Countries Clinical Trials Partnership (EDCTP), Université Catholique de Louvain.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Novel strategies to improve ART adherence, retention in care and quality of life among adolescents living with HIV (ALHIV) are needed. Short-Cycle Therapy (SCT) with 4/5 sequential days on ART, 2/3 days off ART per week has shown non-inferior virological outcomes and high acceptability, but most data are in adults and are very limited for dolutegravir (DTG)-based SCT. METHODS: BREATHER Plus is an ongoing 96-week non-inferiority randomised trial evaluating efficacy, safety and acceptability of SCT (5 sequential days on, 2 days off at the weekend) with DTG/tenofovir (TNV)-based triple ART versus continuous (daily) therapy (CT) in ALHIV. Participants are aged 12 to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic Compounds, 3-RingPiperazinesHIV InfectionsTenofovirAnti-HIV AgentsHumansPyridonesAdolescentOxazinesChildEquivalence Trials as TopicViral LoadRandomized Controlled Trials as TopicMaleFemaleYoung AdultDrug Administration ScheduleDrug Therapy, CombinationQuality of LifeMedication AdherenceMulticenter Studies as TopicPragmatic Clinical Trials as TopicDolutegravir

Stichwörter der Autor:innen

AdolescentsAntiretroviralClinical trialDolutegravirHIVShort-cycle

Substanzen

PyridonesHeterocyclic Compounds, 3-RingPiperazinesOxazinesTenofovirAnti-HIV AgentsDolutegravir

Autor:innen und Institutionen

  • Baylor College of Medicine Children's Foundation, Kampala, Uganda.
  • Department of Paediatrics and Children Health, King Edward VIII Hospital, Enhancing Care Foundation, University of KwaZulu-Natal, Durban, South Africa.
  • Medical Research Council Clinical Trials Unit at University College London, United Kingdom.
  • University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe.
  • Joint Clinical Research Centre, Kampala, Uganda.
  • Moi University Clinical Research Centre, Eldoret, Kenya.

Förderung

  • Medical Research Council
  • European & Developing Countries Clinical Trials Partnership (EDCTP)
  • Université Catholique de Louvain
  • European and Developing Countries Clinical Trials Partnership

Zitieren

APA

Katongole, F., Arumugam, T., Jennings, A., Mutata, C., Ssebunya, P., Wamboi, C., Green, A., Bwakura-Dangarembizi, M., Kityo, C., Siika, A., Archary, M., Jafta, L., Namukwaya, S., Seeley, J., Mugerwa, H., Walker, S., Apoto, N., Thomason, M. J., Ford, D., …, & BREATHER Plus trial team (2025). BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2025.107963

Vancouver

Katongole F, Arumugam T, Jennings A, Mutata C, Ssebunya P, Wamboi C, et al. BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to. Contemporary Clinical Trials. 2025. doi:10.1016/j.cct.2025.107963

BibTeX
@article{Katongole2025,
  author = {Katongole, Fredrick and Arumugam, Tiyara and Jennings, Angus and Mutata, Constantine and Ssebunya, Patrick and Wamboi, Charity and Green, Alexandra and Bwakura-Dangarembizi, Mutsa and Kityo, Cissy and Siika, Abraham and Archary, Moherndran and Jafta, Lungile and Namukwaya, Stella and Seeley, Janet and Mugerwa, Henry and Walker, Simon and Apoto, Naomi and Thomason, Margaret J and Ford, Deborah and Pett, Sarah L and Kekitiinwa, Adeodata R and BREATHER Plus trial team, BREATHER Plus trial team},
  title = {BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to},
  journal = {Contemporary Clinical Trials},
  year = {2025},
  doi = {10.1016/j.cct.2025.107963}
}
Kostenlos starten →